Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Therapeutic applications of adipose-derived mesenchymal stem cells on acute liver injury in canines.

Yan Y., Fang J., Wen X., Teng X., Li B., Zhou Z.

Animal Study on Systemic / IV, published in Res Vet Sci (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Res Vet Sci (2019)
Country
England
Reported sample size
—
Source database
PubMed
PMID
31635840
DOI
10.1016/j.rvsc.2019.09.004
Citations
12

Abstract (original English)

In this study, canine adipose-derived mesenchymal stem cells (cADSCs) therapeutic potential was investigated in artificially induced acute liver injury model by CCl 4 in canines. The primary cADSCs cells were cultured and then intravenously administered into the canine animal model. Six cross-breed dogs were divided into three groups including blank control group, CCl 4 model group, CCl 4 induced cADSCs transplantation group. The results showed that after intraperitoneal injection of CCl 4 solution, the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and Albumin (ALB) in peripheral blood of experimental canines confirmed the correct induction of acute liver injury. Moreover, the liver structure showed clear macroscopic damage. The cADSCs were homed in the liver of the administered animals. The AST, ALT and ALB in the peripheral blood rapidly decreased. H&E and PAS histological evaluation showed that both the structure of canine liver tissue and the ability to synthesize hepatic glycogen could be restored to the control level after cADSCs transplantation. Therefore, cADSCs can play a therapeutic role in the recovery of liver injury. Overall, this study demonstrates that the primary cADSCs transplantation into the acute liver injury model induced by intravenous injection can play a certain therapeutic role in the recovery of liver in canines. These resu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAdministration, IntravenousAlanine TransaminaseAnimalsAspartate AminotransferasesBiomarkersCarbon TetrachlorideChemical and Drug Induced Liver InjuryDogsFemale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research